Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You have a sense if IPIX would run a Phase 2 with two interventional arms 1) Brilacidin alone and 2) Brilacidin with Remdesivir??
Your in my prayers. GOD BLESS.
So based on your beliefs or your own facts about covid 19,
===>
nurses and doctors working in the emergency rooms with covid 19 patients should not wear protective gear
===>
because covid is an overwhelming age category disease > 70 and/or bad underlying, pre-existing conditions disease????
A recent reminder that a 17 year old Georgia boy lost both his parents 59 and 57 years old to covid 19 in a span of one week.
I think Fauci is very busy, but maybe you could email his 2nd in command and others working with his 2nd in command.
https://www.niaid.nih.gov/about/director-contacts
I was initially looking at the first 7 below Fauci's name
in the link above.
Principal Deputy Director to Fauci has email and ph# in the
following link:
https://ned.nih.gov/search/ViewDetails.aspx?NIHID=0012489749
Please don't put out a rushed email. You may want to have it peer reviewed by others here or other doctors you know before you send it out. If you are really a MD ER and have seen this for 30 years and can put things in proper words -- then go for it.
Best to take the weekend plus the following week to write convincingly and make your strong points. A 1-2 paragraph email is not going to cut it.
Have at it!!!
I would like to see several dosing regimens per each active Brilacidin treatment arm. Leave out the mild cases.
Moderate-Severe-Critical (5:3:1 ratio) in each active treatment arm.
Steroids for coronavirus, maybe/maybe not
https://www.technology.org/2020/02/19/steroids-should-not-be-used-to-combat-the-coronavirus/
Were any Resmedivir covid-19 results publicly released by Gilead from the lab researchers testing of Resmedivir (Gilead drug) back in January 2020 before the lab researchers published the following Feb 4 2020 document (invitro lab vero cell testing)???
https://www.nature.com/articles/s41422-020-0282-0
HOMEWORK FOR YOU:: Go read the Resmedivir website and see if Gilead PRed to the public any invitro vero cell results or any human kidney or human lung cell results for COVID-19 before the Resmedivir research lab test results article was published??
In addition :
Published article shows no human kidney cell results for Resmedivir!!
Published article shows no human lung cell results for Resmedivir!!
One day after the published article:
Feb 5 2020 Resmedivir begins Phase 3 trial
https://www.genengnews.com/news/coronavirus-gileads-remdesivir-begins-trials-as-researchers-publish-positive-in-vitro-results/
That IS NOT WHAT THE PR SAYS!
WAKEFIELD, MA – March 9, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company has been notified by one of the 12 Regional Biocontainment Labs (RBLs) in the United States that it received shipment of Brilacidin, the Company’s defensin mimetic drug candidate, for testing against SARS-CoV-2, the specific coronavirus responsible for COVID-19. Brilacidin is immediately being placed into queue and the Company anticipates confirmation of the testing schedule as well as procedures for the studies later this week.
You seem concerned about the strength and duration of the oral Bril medicine to treat UC via directly targeting the colon.
Perhaps the phase 2 trial will have 2 pills taken per day at seperate intervals to extend the Bril coverage in the UC area for most of the day.
Or maybe Bril is powerful enough they don't need to do this.
BDD can make tweaks necessary to start delivery of the medicine closer to the UC area.
Don't understand what mean by just passing thru?
There is continuous contact with the colon effected area while the
dispersion of the medicine works it way thru to the end of the colon.
i could have wrote this too...where's your verification?
Why is a CMO needed right away. For now, CoronaVirus with Brilacidin being tested independently, LW negotiating BOM, B-UC next phase trial design probably in discussions with IPIX's GI consultant Dr. Farraye and BP.
Yeah, take a look at nnvc runup, they have never run a clinical trial nor developed any vaccines. They are being linked to research for a coronavirus vaccine. From 3ish to highest 19 ish the past 8 weeks. Backed off to 9ish, but still holding quite remarkable gains for no clinical trials and limited cash.
Were you at the JPM conference?
Yeah, LW funding should be only if it's a pool of investors that want to run this trial.
Thank you for revealing this.
If you mean everyone has their own opinion, of course.
I said maybe there is something of value...and LW is a professional deal maker given the lead role now on BOM negotiations.
If LW was selected to lead out-licensing negotiations, then maybe something of value is there.
We shall see.
Everyone is entitled to their opinion.
Soligenix is running a Phase 3 because their drug does reduce # days of Grade 3/4 OM. They are not a Grade 3/4 prevention which BOM could be, and BOM has shown to reduce # days of Grade 3/4 OM.
So maybe BOM trial should be run to an interim analysis of 200 patients and see what those results are.
January 29, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, has further engaged Locust Walk, a leading global life sciences transaction firm serving as its strategic advisor, to lead the Company’s out-licensing negotiations for rights to oral rinse Brilacidin for the treatment of Oral Mucositis (OM).
Did you see examples of Locust Walk offering financial assistance on their website or thru news outlets? It could happen since LW is directly involved in BOM negotiations...maybe Ulcerative Colitis prelim talks as well.
My thought would be someone runs the trial and an interim analysis is done after 200 patients. If results not showing grade 3/4 OM prevention, and reduction in days having severe OM, then rest of trial is scrapped.
Question is would the party paying for the trial owe money for the rest of the trial that was never run?
I would think no payment required for not running remaining part of the trial. Trial would be halted.
Soligenix is running their IV Delivery OM Phase 3 and their Phase 2 did not show prevention of OM, nor does their clinical trial endpoint for Phase 3 show OM prevention.
They need a deal - 1 of 2.
At least this time they have a top notch, global biolife sciences negotiator and dealmaker to take the lead.
I would prefer it's not sold whole - just the K-Ovarian with the Orphan Drug Designation. It's the farthest along and not the whole platform.
There is no first right of refusal for BOM if that's the drug you meant. I guess your talking B-UC.
If pressed you give up K Ovarian.
There is some value, but it should be a last resort, talking cancer.
Yes, they need BOM or a deal for B-UC or a LW type M&A of the B platform. Or something with K - plz don't give all of K away.
Jan 29 it was stated Locust Walk was leading negotiations for BOM.
It may well be there are multiple regional licenses in play for BOM.
This would lessen the risk for each parties trial cost and upfront payment as the cost is spread out over multiple parties.
Could allow for a decent upfront in total.
Let's wait and see how this plays out...
And who knows, after the B-UC Phase 1, maybe Locust Walk will be entering a second asset negotiation.
After reading his contract, looks like he resigned on his own.
Appears the contract does not specifically say at will.
Part of your post highlighting lease auto renewal was in the 10Q.
Why did you say otherwise in another post?
"You mean it was not an at will contract?" Did I say that?
It was an at will contract.
But you said....
"He resigned, but probably was given the end of December to resign or he would be let go."
....and that ultimatum (Termination without Cause) would have triggered the requirement to continue to pay him for a year.
ME: IF it was at will, he could be let go, no cause/reason needed.
DEFINITION: In an at-will employee relationship, the employer does not need a good reason to terminate your employment.
Post 81892
The 10-Q for the period ended September 30, 2018 and filed on 11/8/18 said this:
"On September 30, 2018, the Company’s lease agreement with Cummings Properties automatically renewed. The lease is for a term of five years ending on September 30, 2023, and requires monthly payments of approximately $19,000."
"He resigned, but.......
You mean it was not an at will contract?
"Novartis compound known......
IF the above contract applies then yes, he probably wouldn't resign.
Here's a fantasy or not:
Maybe Novartis/BDD compound is B and Dr B consults for B in capacity for both IPIX and Novartis when a deal is completed between the two companies.
Question here in last paragraph may be, was IPIX on signature for automatic renewal at the time. The 10Q would not be where such evidence resides. The 10Q from 2018 is a statement of facts, but not the actual agreement steps leading to the transaction.
He resigned, but probably was given the end of December to resign or he would be let go.
Locust Walk in, Dr B out.
Novartis compound known or unknown to Dr B, unrelated to his departure.
They should use a placebo arm as B-UC is a big market and comparison of placebo and control arm difference can be compared to current UC drugs on the market.
If I recall BUP had no placebo arm.
Yes, was good news today.
Of course, trial design probably dictated by BPs.
BDD has done well...we'll see where they fit.
You like rewording another person's post to exact opposite meaning in the last sentence.
I understand critiques, but everyone deep down inside should hope whatever company whatever drug, it is a success for those out there who need it. How about an oral pill for B-UC, if its side effects are less serious than biologics?
30-50 million hmmm...how did Soligenix get all the money for their Phase 3 OM trial...I didn't see any license deal done with them, they probably raised thru equity, because their product does not prevent OM so no license interest. And did they raise even $25 million for their OM Phase 3?
OM should be a simple trial to run.
It is a drug trial, not company specific trial.
DR Stephen Sonis is a consultant for IPIX, maybe he's the only necessity.
No more risk than partnering with 3 employees and assuming all costs.
It's a drug trial run by independent investigators.
A favorable outcome and the licensee has long term recurring profits.
Licensee should have an interim analysis in place at some point in the trial.
Hire Dr. Sonis as a consultant.